News CrystalGenomics, a partner biopharmaceutical company of Standigm, finds first evidence to a new AI-driven drug for cancer.
CrystalGenomics, Inc., Standigm’s partner company, today announced a drug predicted by Standigm’s artificial intelligence technology showed the evidence that it may reuse for cancer treatment. The drug is an FDA-proved drug for other therapeutic uses. It has been only three months to sign the partnership between Standigm, Inc. and CrystalGenomics, Inc.
Date : September 27-28 2017
Location : London, UKJinhan Kim, Standigm CEO, spoke at Artificial Intelligence in Drug Development Congress 2017.
Date : July 26-27, 2017
Location : Boston, USAJinhan Kim, Standigm CEO, spoke about “artificial applicable intelligence in drug discovery and repositioning” at AI PHARMA INNOVATION.
Seoul, Korea, South, June 22, 2017 - The advent of artificial intelligence (AI) has global pharmaceutical companies and startups in a race to develop new products and services in all sectors. The field of healthcare is no exception with the U.S. leading the way in AI startups. Many startups partner with bigger companies or become part of the latter. The National Information Society Agency released a report Tuesday on promising AI startups in Korea, including six in the field of healthcare – Neofect, Vuno, Tomocube, Lunit, Standigm, and Bitfinder.